Akari Therapeutics (AKTX) Current Assets (2011 - 2026)

Akari Therapeutics has disclosed Current Assets across 16 years of filings, most recently posting $3.6 million for Q1 2026.

• Current Assets for Q1 2026 came in at $3.6 million, up 7.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (up 7.17% YoY), and the FY2025 annual result was $5.5 million, up 85.03% from the prior year.
• Current Assets came in at $3.6 million for Q1 2026 at Akari Therapeutics, down from $5.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $13.8 million in Q4 2022 to a low of $2.7 million in Q3 2024.
• The 5-year median for Current Assets is $3.3 million (2025), against an average of $4.6 million.
• Across the five-year window, Current Assets slumped 68.58% in 2023 and surged 85.03% in 2025, its largest moves.
• Akari Therapeutics' Current Assets stood at $13.8 million in 2022, then plunged by 68.58% to $4.3 million in 2023, then tumbled by 32.0% to $3.0 million in 2024, then soared by 85.03% to $5.5 million in 2025, then plunged by 34.29% to $3.6 million in 2026.
• The last three Current Assets figures came in at $3.6 million (Q1 2026), $5.5 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.